Lowell Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Lowell Therapeutics (founded 2018, Lowell, Massachusetts; CEO James Wilkie) developed Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy (CRRT) in acute kidney injury patients — a lyophilized formulation of nafamostat, a broad-spectrum synthetic serine protease inhibitor with anticoagulant, anti-inflammatory and potential anti-viral activity. Niyad held FDA Breakthrough Device Designation; its second pipeline asset, LTX-608, was a direct IV formulation for acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Founded in 2018 in Lowell, Massachusetts (SEC Form D: incorporated 2018; James Wilkie, CEO).
- Acquired
Acquired by Talphera, Inc. (the company formerly known as AcelRx Pharmaceuticals) for $32.5 million — Mergr records the transaction on November 15, 2021; PitchBook records the completed M&A on January 10, 2022.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.